Assessment of Isoniazid Preventive Therapy and Incidence of Tuberculosis among People Living with Human Immunodeficiency Virus Seeking Care in an Anti-retroviral Therapy Center, Puducherry

Indian J Public Health. 2024 Jan 1;68(1):15-20. doi: 10.4103/ijph.ijph_206_23. Epub 2024 Apr 4.

Abstract

Background: One in three deaths among people living with human immunodeficiency virus (PLHIV) is due to Tuberculosis. Isoniazid preventive therapy (IPT) was implemented in antiretroviral therapy (ART) center Puducherry in July 2017.

Objectives: We have determined the proportion of PLHIV who were eligible, initiated, completed IPT and also the incidence of tuberculosis before and after implementation of IPT.

Materials and methods: It was a facility based longitudinal descriptive study. All PLHIV, aged 10 years and above, seeking care in ART Centers was included. The number of PLHIV eligible, initiated and completed IPT was summarized as proportion with 95% CI.

Results: Among the registered PLHIV (999), the proportion of PLHIV those were found eligible for IPT was 93% [95% CI (91.24%-94.67%)] and initiated on IPT was 92% [95% CI (90.20%-93.95%)]. Completion rate of IPT was 96.3% [95% CI (94.59%-97.63%)].

Conclusion: Initiation of IPT was relatively less among newly registered PLHIV as compared to older cohort of PLHIV.

MeSH terms

  • Adolescent
  • Adult
  • Antitubercular Agents* / therapeutic use
  • Child
  • Female
  • HIV Infections* / drug therapy
  • HIV Infections* / epidemiology
  • Humans
  • Incidence
  • India / epidemiology
  • Isoniazid* / therapeutic use
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Tuberculosis* / epidemiology
  • Tuberculosis* / prevention & control
  • Young Adult

Substances

  • Isoniazid
  • Antitubercular Agents